as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹1,258.9
Change
-15.7 (-1.23%)
Open
₹1,275.0
Prev. Close
₹1,274.6
Day High
₹1,280.9
Day Low
₹1,255.0
Volume Analysis
Traded
30,256
Delivered
17,349
Delivery %
57.34%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (35.0%)
Weaknesses (1)
- •Promoter holding is falling
Opportunities (2)
- •Strong 3-year EPS growth (16.8%)
- •Strong 3-year revenue growth (22.9%)
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,300.76 | ₹1,290.83 | ₹1,274.86 | ₹1,264.93 | ₹1,248.96 | ₹1,239.03 | ₹1,223.06 |
| Fibonacci | ₹1,290.83 | ₹1,280.94 | ₹1,274.82 | ₹1,264.93 | ₹1,255.04 | ₹1,248.92 | ₹1,239.03 |
| Camarilla | ₹1,266.02 | ₹1,263.65 | ₹1,261.27 | ₹1,264.93 | ₹1,256.53 | ₹1,254.15 | ₹1,251.78 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-16.15%
1 Week
-2.81%
1 Month
-4.25%
3 Months
-12.18%
6 Months
-3.92%
1 Year
-20.6%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹532.68
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
16.6%
Net margin 20.62% × asset turnover 0.44x × equity multiplier 1.83x
Company Overview
Sector
Healthcare
Market Cap
₹17,618 Cr
P/E (TTM)
26.9
ROE
18.7%
Book Value
₹282.0
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 24 Sep 2026. Not investment advice.
TopFund Analysis
Eris Lifesciences Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 65/100. The strongest factor is Business Quality (86/100), while Momentum (13/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (35.0%); promoter holding is falling. FII holding has been falling.
TopFund Score — Fundamentals Quality
65/100 — GoodData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- −Stock is trading at 4.51 times its book value
- −Tax rate seems low
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Eris Lifesciences allotted 1,55,264 equity shares under ESOP-2021 on 22 September 2026.
Mr. Akhil Awasthi appointed Additional Independent Director for five years from 26 September 2026.
Executive Director and COO Krishnakumar Vaidyanathan resigns; relieved effective 30 September 2026.
Eris clarified 9 September 2026 media reports on loan value, citing prior exchange disclosure.
Eris Lifesciences avails ₹45 crore term loan from Axis Bank to meet liabilities.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 467 | 505 | 486 | 551 | 720 | 741 | 727 | 705 | 773 | 792 | 807 | 757 | 873 |
| Expenses + | 297 | 324 | 311 | 402 | 470 | 477 | 477 | 453 | 496 | 504 | 526 | 484 | 577 |
| Operating Profit | 170 | 181 | 176 | 148 | 250 | 265 | 250 | 252 | 277 | 288 | 282 | 272 | 296 |
| OPM % | 36.0% | 36.0% | 36.0% | 27.0% | 35.0% | 36.0% | 34.0% | 36.0% | 36.0% | 36.0% | 35.0% | 36.0% | 34.0% |
| Other Income + | 1 | 3 | 4 | 15 | 2 | 5 | 4 | 8 | 4 | 3 | -17 | 2 | 2 |
| Interest | 17 | 16 | 18 | 33 | 60 | 59 | 57 | 54 | 49 | 50 | 49 | 46 | 47 |
| Depreciation | 41 | 42 | 46 | 54 | 76 | 80 | 81 | 77 | 71 | 69 | 70 | 70 | 72 |
| Profit before tax | 112 | 126 | 116 | 77 | 116 | 129 | 116 | 129 | 161 | 173 | 145 | 159 | 179 |
| Tax % | 17.0% | 3.0% | 12.0% | -4.0% | 22.0% | 25.0% | 25.0% | 21.0% | 22.0% | 22.0% | 25.0% | -75.0% | 20.0% |
| Net Profit + | 94 | 122 | 101 | 80 | 90 | 96 | 87 | 102 | 125 | 134 | 109 | 279 | 143 |
| EPS in Rs | 7 | 9 | 8 | 5 | 6 | 7 | 6 | 7 | 9 | 9 | 7 | 20 | 10 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 546 | 597 | 750 | 856 | 982 | 1,074 | 1,212 | 1,347 | 1,685 | 2,009 | 2,894 | 3,129 | 3,230 |
| Expenses + | 427 | 425 | 480 | 533 | 637 | 702 | 781 | 858 | 1,146 | 1,332 | 1,876 | 2,009 | 2,092 |
| Operating Profit | 118 | 172 | 269 | 322 | 345 | 372 | 431 | 489 | 539 | 677 | 1,018 | 1,120 | 1,138 |
| OPM % | 22.0% | 29.0% | 36.0% | 38.0% | 35.0% | 35.0% | 36.0% | 36.0% | 32.0% | 34.0% | 35.0% | 36.0% | 35.0% |
| Other Income + | 7 | 3 | 25 | 26 | 31 | 12 | 9 | 22 | 9 | 22 | 18 | -9 | -9 |
| Interest | 0 | 0 | 1 | 11 | 23 | 2 | 2 | 4 | 26 | 85 | 231 | 193 | 191 |
| Depreciation | 16 | 20 | 23 | 26 | 36 | 50 | 43 | 65 | 117 | 183 | 315 | 280 | 281 |
| Profit before tax | 109 | 154 | 270 | 312 | 317 | 331 | 394 | 442 | 405 | 431 | 489 | 639 | 657 |
| Tax % | 18.0% | 13.0% | 9.0% | 6.0% | 8.0% | 11.0% | 10.0% | 8.0% | 8.0% | 8.0% | 23.0% | -1.0% | — |
| Net Profit + | 89 | 135 | 247 | 295 | 291 | 297 | 355 | 406 | 374 | 397 | 375 | 648 | 666 |
| EPS in Rs | 6,489 | 9,714 | 18 | 21 | 21 | 22 | 26 | 30 | 28 | 29 | 26 | 45 | 47 |
| Dividend Payout % | 0.0% | 63.0% | 0.0% | 0.0% | 0.0% | 13.0% | 21.0% | 20.0% | 26.0% | 0.0% | 28.0% | 16.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 266 | 299 | 553 | 848 | 1,137 | 1,283 | 1,563 | 1,895 | 2,182 | 2,573 | 2,841 | 3,889 |
| Borrowings + | 1 | 0 | 1 | 377 | 176 | 0 | 7 | 84 | 877 | 2,781 | 2,478 | 2,359 |
| Other Liabilities + | 91 | 98 | 124 | 170 | 175 | 205 | 202 | 233 | 337 | 1,366 | 1,415 | 861 |
| Total Liabilities | 357 | 397 | 692 | 1,408 | 1,502 | 1,502 | 1,785 | 2,226 | 3,410 | 6,734 | 6,747 | 7,123 |
| Fixed Assets + | 72 | 71 | 232 | 771 | 761 | 875 | 854 | 918 | 2,568 | 4,319 | 5,306 | 5,188 |
| CWIP | 0 | 0 | 0 | 0 | 3 | 4 | 2 | 27 | 22 | 20 | 67 | 171 |
| Investments | 167 | 190 | 303 | 365 | 356 | 78 | 294 | 520 | 37 | 16 | 67 | 62 |
| Other Assets + | 119 | 136 | 157 | 271 | 383 | 544 | 636 | 761 | 783 | 2,379 | 1,307 | 1,702 |
| Total Assets | 357 | 397 | 692 | 1,408 | 1,502 | 1,502 | 1,785 | 2,226 | 3,410 | 6,734 | 6,747 | 7,123 |
| Equity Capital | 0 | 0 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 90 | 131 | 200 | 235 | 223 | 271 | 375 | 378 | 292 | 486 | 1,065 | 538 |
| Cash from Investing Activity + | -92 | -44 | -184 | -590 | -5 | 123 | -323 | -320 | -975 | -1,828 | -78 | -369 |
| Cash from Financing Activity + | 0 | -84 | -24 | 363 | -221 | -335 | -82 | -45 | 688 | 1,380 | -881 | -314 |
| Net Cash Flow | -2 | 4 | -8 | 8 | -3 | 60 | -30 | 14 | 5 | 38 | 105 | -145 |
| CFO/OP | 96 | 97 | 94 | 94 | 85 | 87 | 103 | 94 | 68 | 87 | 114 | 59 |
| Free Cash Flow | 77 | 108 | 150 | 210 | 186 | 125 | 350 | 258 | -550 | 357 | 910 | 241 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 17.37% | 17.41% | 15.2% | 14.3% | 18.47% | 18.73% | 18.64% | 18.59% | 18.57% | 17.97% | 19.33% | 19.39% |
| Promoters | 54.91% | 54.9% | 54.9% | 54.88% | 54.87% | 54.86% | 54.85% | 54.83% | 54.85% | 54.85% | 53.92% | 54.14% |
| FII | 13.2% | 13.13% | 14.27% | 14.59% | 8.01% | 8.36% | 8.43% | 8.39% | 7.21% | 6.85% | 6.39% | 5.76% |
| DII | 14.52% | 14.55% | 15.63% | 16.23% | 18.64% | 18.07% | 18.07% | 18.18% | 19.36% | 20.31% | 20.35% | 20.71% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Eris Lifesciences Limited (this stock) | 17,618 | 26.9 | 4.5 | 18.7% |
| Poly Medicure Limited | 17,479 | 54.6 | 5.63 | 9.02% |
| Cohance Lifesciences Ltd | 17,290 | 161.0 | 4.43 | 4.89% |
| Jubilant Pharmova Ltd | 17,118 | 44.1 | 2.41 | 6.53% |
| Pfizer Ltd | 18,303 | 119.0 | 13.25 | 19.8% |
| Onesource Specl Pharma L | 18,377 | — | 3.15 | -1.09% |
| Alivus Life Sciences Ltd | 16,820 | 47.8 | — | — |
Which Mutual Funds Hold Eris Lifesciences Limited?
Frequently Asked Questions about Eris Lifesciences Limited
Eris Lifesciences Limited (ERIS) closed at ₹1,258.9 on NSE on 25 September 2026, down 15.7 (1.23%) from the previous close.
Eris Lifesciences Limited trades on the NSE (National Stock Exchange of India) under the symbol ERIS.
Eris Lifesciences Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 26.9.
Eris Lifesciences Limited has a dividend yield of 0.57%.
Eris Lifesciences Limited's 52-week high is ₹1,740.0 and its 52-week low is ₹1,200.0.
Eris Lifesciences Limited has a market capitalisation of ₹17,618 crore.
Eris Lifesciences Limited has a TopFund Quality Score of 65/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Eris Lifesciences Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.